KNSA (Kiniksa Pharmaceuticals International) Price-to-Operating-Cash-Flow : 46.01 (As of May. 30, 2025)

View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International Price-to-Operating-Cash-Flow?

As of today (2025-05-30), Kiniksa Pharmaceuticals International's share price is $27.375. Kiniksa Pharmaceuticals International's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.60. Hence, Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow Ratio for today is 46.01.

The historical rank and industry rank for Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow or its related term are showing as below:

KNSA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 19.72 Med: 59.27 Max: 222.39
Current: 46.21

During the past 9 years, Kiniksa Pharmaceuticals International's highest Price-to-Operating-Cash-Flow Ratio was 222.39. The lowest was 19.72. And the median was 59.27.

KNSA's Price-to-Operating-Cash-Flow is ranked worse than
80.67% of 688 companies
in the Drug Manufacturers industry
Industry Median: 17.14 vs KNSA: 46.21

Kiniksa Pharmaceuticals International's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $0.29. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.60.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Kiniksa Pharmaceuticals International was 97.00% per year.

During the past 9 years, Kiniksa Pharmaceuticals International's highest 3-Year average Operating Cash Flow per Share Growth Rate was 12.40% per year. The lowest was -63.20% per year. And the median was -12.60% per year.

Kiniksa Pharmaceuticals International Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals International Price-to-Operating-Cash-Flow Chart

Kiniksa Pharmaceuticals International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

182.68

94.81

54.94

Kiniksa Pharmaceuticals International Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															65.33	43.72	162.27	54.94	37.33

Competitive Comparison of Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Kiniksa Pharmaceuticals International Price-to-Operating-Cash-Flow Calculation

Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	27.375	/	0.595
	=	46.01

Kiniksa Pharmaceuticals International's Share Price of today is $27.375.
Kiniksa Pharmaceuticals International's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.60.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Kiniksa Pharmaceuticals International Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiniksa Pharmaceuticals International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

23 Old Bond Street, Floor 3, London, GBR, W1S 4PZ

Website

https://www.kiniksa.com

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Executives

Sanj K Patel	director, 10 percent owner, officer: Chairman & CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eben Tessari	officer: Chief Business Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini	officer: Chief Medical Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael R Megna	officer: Chief Accounting Officer	1050 HINGHAM STREET, ROCKLAND MA 02370
Ross Moat	officer: Group VP & Rilonacept GM	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa	officer: Interim CFO	C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Barry D Quart	director	C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano	officer: Chief Clinical Dev. Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	10 percent owner, officer: Chief Legal Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063